Philogen (PHIL) H1 2025 earnings summary

Executive summary

• Announced major licensing agreements with RayzeBio (BMS) and Racebio for OncoACP3/OncoCP3, each with $350 million upfront and up to $1 billion in milestones and royalties, significantly strengthening financial resources.

• Focused on advancing late-stage clinical programs, especially Nidlegy and Fibromun, and expanding the pipeline with new trials and molecules, supported by a vertically integrated R&D and manufacturing model.

• Revenues from contracts with customers rose to €5.5 million, with total revenues reaching €8.7 million, up €7 million year-over-year, driven by clinical trial progress and product sales.

• Expanded operations with new clinical offices in Milan, facility upgrades in Monteriggioni and Zurich, and increased research and clinical teams.

• Voluntary withdrawal of Nidlegy EMA application to collect additional CMC and clinical data, with resubmission planned.

Financial highlights

• Cash and cash equivalents at the end of H1 2025 were €100 million, with liquidity exceeding €350 million after major licensing inflows.

• Total revenues for H1 2025: €8.7 million, up €7 million year-over-year, driven by contract manufacturing, licensing, and product sales.

• EBITDA: -€13.9 million (improved from -€15.2 million in H1 2024); EBIT: -€15.8 million; net loss: €14.9 million (vs. €15.5 million in H1 2024).

• Net financial position: €88.5 million surplus, with €100 million in cash and €88.8 million in liquid financial assets.

• Operating costs increased 33% year-over-year, mainly due to higher R&D, clinical trial, and personnel expenses.

Outlook and guidance

• Plans to invest new resources in late-stage products and launch additional global trials in non-melanoma skin cancers.

• Regulatory resubmission for Nidlegy planned for mid-2026, with ongoing dialogue with authorities and US Phase III two-thirds enrolled.

• Anticipates communicating first-line soft tissue sarcoma trial results and progressing glioblastoma trials in coming months.

• Multiple Phase I clinical trials for new drug candidates planned over the next 24 months.

• Continued collaborations with Sun Pharma, Pfizer, Janssen, Bracco, MSD, and RayzeBio.